Figures & data
Table 1 Clinical characteristics and biomarker concentrations of the study subjects across the discovery cohort (n=90)
Table 2 Clinical characteristics and biomarker concentrations of the study subjects across the replication cohort (n=135)
Table 3 ROC analysis for sputum biomarkers in the discovery cohort
Table 4 Multivariate stepwise analysis of all subjects with sputum biomarker as the dependent variable in patients with asthma, COPD, and ACOSTable Footnotea
Figure 1 Correlation of sputum NGAL with pre-FEV1% predicted in patients with asthma, COPD, and ACOS in the discovery (A) and in the replication cohorts (B).
![Figure 1 Correlation of sputum NGAL with pre-FEV1% predicted in patients with asthma, COPD, and ACOS in the discovery (A) and in the replication cohorts (B).](/cms/asset/3f6a0e16-d537-46d3-a45a-5b5454850d9c/dcop_a_113484_f0001_b.jpg)
Figure 2 Expression levels of sputum biomarkers in patients with asthma, COPD, and ACOS in the discovery (A) and replication cohorts (B).
Abbreviations: ACOS, asthma–COPD overlap syndrome; IL, interleukin; MPO, myeloperoxidase; NGAL, neutrophil gelatinase-associated lipocalin; YKL-40, chitinase-3-like protein 1.
![Figure 2 Expression levels of sputum biomarkers in patients with asthma, COPD, and ACOS in the discovery (A) and replication cohorts (B).](/cms/asset/17fc4ba3-61d8-4b6c-bb52-45462dd28f55/dcop_a_113484_f0002_b.jpg)